Dolutegravir is an effective option to treat HIV infection.
The drug in phase 3 of clinical research is as effective and safe as raltegravir and offers more resistance the mutations of the virus.
a new drug against the virus of the AIDS (HIV-1), called dolutegravir, Spain, January of 2013- a multicenter study published in the journal The Lancet compared with raltegravir, another antiretroviral of the same family marketed since 2007. The study concludes that the two drugs have the same efficacy and safety. In other studies, dolutegravir has proved to be superior to the treatments of reference, more resistant to mutations in HIV-1, does not need to be enhanced with other medications and can manage in a single daily dose. This makes the dolutegravir an effective option to treat HIV-1 infection. Researchers of the Institute of biomedical research of Bellvitge (IDIBELL) at the Hospital Universitario de Bellvitge have participated in the study.
Daniel Podzamczer, program director of HIV/AIDS of the service of infectious diseases of the Bellvitge HU and researcher at the IDIBELL, who participated in the study.
Both dolutegravir and raltegravir are part of the family of integrase inhibitors, a group of drugs that block an enzyme the virus involved in your replication process. This group of antiretroviral drugs inhibit the virus more quickly, are well tolerated and have few interactions with other medications. Raltegravir was the first drug of this family to be approved, the year 2007. Summer 2012 at United States adopted the second, elvitegravir, which is pending approval in Europe, and expected that dolutegravir can begin to market during the year 2013.
800 patients
More than 800 people which had been newly infected by HIV-1 participated in the study. Patients who have participated in the trial are clinical hospitals around the world that are part of the SPRING-2 study. Seventeen patients contributed the Bellvitge University Hospital. Half of the participants were treated with raltegravir and the other half with dolutegravir. In both cases, the treatment was complemented, as shown, with two reverse transcriptase inhibitors family antiretrovirals.
Response to treatment was similar in both cases, both in terms of effectiveness as side effects. The director of the program of HIV / AIDS of the service of infectious diseases of the Hospital Universitario Bellvitge and researcher at the IDIBELL, Daniel Podzamczer, emphasizes that dolutegravir can be administered in a single daily pill, while the daily dose of raltegravir s has to divide in two tablets. Unlike elvitegravir, Col·laboradors underlines that “dolutegravir does not need to be boosted with ritonavir [antiretroviral used in low doses to boost the effect of other drugs against HIV] or with cobicistat and seems to have a genetic barrier higher than the other two drugs, implying that more mutations of the virus would be necessary to become resistant”.
Dolutegravir manages along with other antiretrovirals, and expected that it will be marketed in a single tablet. However, in the editorial that accompanied the publication of the study speculated that dolutegravir could be effective without combining it with other antiretrovirals, which would become the first able to be administered as monotherapy, integrase inhibitor which would considerably reduce the side effects and cost of treatment. Still, however, there is no sufficient data enabling you to think about this possibility.
who we are
Institute of biomedical research of Bellvitge ( IDIBELL ) is a research centre created in 2004. It is participated by the Hospital Universitario de Bellvitge of the Catalan Institute of <? NS prefix = st1 ns = “urn: schemas-microsoft-com: office:smarttags” / >
do
<? NS prefix = v ns = “urn: schemas – microsoft – com:vml” / >
–
Article reference
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, C Orkin, Bloch M, Col·laboradors D *, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; on behalf of the SPRING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority study SPRING-2. Lancet. 2013 Jan 7. PII: S0140-6736 (12) 61853-4. DOI: 10.1016/S0140-6736 (12) 61853-4. [Epub ahead of print]
* Investigator of l ’ l IDIBELL ’ Hospital Universitari de Bellvitge.
